Pediatric cancer research cut from spending legislation at last minute Republicans quietly removed hard-won pediatric cancer bills

DoD Ovarian Research Program FY25 anticipated funding opportunities

The FY25 Defense Appropriations Act is anticipated to provide funding for the Ovarian Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members and all women impacted by this disease. The Congressionally Directed Medical Research Programs, or CDMRP, at the U.S. Army Medical Research and Development Command is the program office managing these anticipated FY25 funding opportunities.

January 10, 2025

Vol.51 No.01

Drugs & Targets

FDA approves Ryoncil for steroid-refractory acute graft versus host disease in pediatric patients

FDA approved Ryoncil (remestemcel-L-rknd), an allogeneic bone marrow-derived mesenchymal stromal cell therapy, for steroid-refractory acute graft versus host disease in pediatric patients two months of age and older. Ryoncil is the first FDA-approved MSC therapy.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Repurposed drug has promising efficacy in shrinking NSCLC tumors

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Center researchers showed.

December 13, 2024

Vol.50 No.46

Drugs & Targets

Dewpoint Therapeutics and ConcertAI form drug development partnership

Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186.

December 13, 2024

Vol.50 No.46

In Brief

The Lilabean Foundation for Pediatric Brain Cancer raises $900K

The Lilabean Foundation for Pediatric Brain Cancer Research raised $900,000 at its 13th Annual Lilabean Foundation Fall Ball, held on Saturday, November 2. Proceeds from the Fall Ball will directly fund groundbreaking research initiatives focused on discovering new treatments and improving survival rates for children fighting pediatric brain cancer.

November 22, 2024

Vol.50 No.44

In Brief

SU2C announces grants supporting research in six cancer types

Stand Up To Cancer announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal, and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.

October 18, 2024

Vol.50 No.39

Pediatric cancer research cut from spending legislation at last minute

Republicans quietly removed hard-won pediatric cancer bills

YOU MAY BE INTERESTED IN

DoD Ovarian Research Program FY25 anticipated funding opportunities

FDA approves Ryoncil for steroid-refractory acute graft versus host disease in pediatric patients

Repurposed drug has promising efficacy in shrinking NSCLC tumors

Dewpoint Therapeutics and ConcertAI form drug development partnership

The Lilabean Foundation for Pediatric Brain Cancer raises $900K

SU2C announces grants supporting research in six cancer types

Renew today!

Subscriber content

Never miss an issue!

Login